Close Menu

NEW YORK – Agilent Technologies announced Thursday its PD-L1 IHC 22C3 pharmDx received approval from the US Food and Drug Administration as a companion diagnostic for Merck's pembrolizumab (Keytruda) on the Dako Omnis platform.

The test identifies patients with non-small cell lung cancer who are appropriate for first-line monotherapy with pembrolizumab. The Dako Omnis platform provides a fully automated solution for staining tumor samples with a high-throughput diagnostic service. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.